NCT00551564View on ClinicalTrials.gov

Study to Determine the Utility of Novel Technologies and Biomarkers to Measure Human Response to Rosiglitazone Maleate

PHASE1CompletedINTERVENTIONAL

Enrollment

36

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

September 8, 2008

Study Completion Date

September 8, 2008

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

rosiglitazone maleate

Rosiglitazone tablets 4 mg dose will be administered orally by subjects

Trial Locations (1)

91911

GSK Investigational Site, Chula Vista

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY

NCT00551564 - Study to Determine the Utility of Novel Technologies and Biomarkers to Measure Human Response to Rosiglitazone Maleate | Biotech Hunter | Biotech Hunter